PT-141 vs Sermorelin
A comprehensive, data-driven comparison of PT-141 (Bremelanotide) and Sermorelin (GHRH 1-29). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | PT-141 Bremelanotide, Vyleesi | Sermorelin GHRH 1-29, GRF 1-29 |
|---|---|---|
| FDA Status | FDA Approved | Withdrawn (off-label use continues) |
| Category | Sexual Health | Growth Hormone |
| Primary Use | Hypoactive sexual desire disorder (HSDD) in women | Growth hormone deficiency and anti-aging |
| Weight Loss % | N/A | N/A |
| Monthly Cost | $800 - $1,200/mo | $150 - $350/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 1.75mg as needed, at least 45 min before activity | 200-500mcg daily before bed |
| Frequency | As needed | Daily |
| Mechanism | Melanocortin receptor agonist that activates central nervous system pathways involved in sexual arousal | Bioidentical analog of growth hormone releasing hormone (GHRH) that stimulates natural GH production |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Moderate |
| Clinical Trial Phase | Approved | N/A |
Key Differences
- 1PT-141 is FDA-approved, while Sermorelin is currently withdrawn (off-label use continues).
- 2Sermorelin is generally more affordable ($150 - $350/mo) compared to PT-141 ($800 - $1,200/mo).
- 3PT-141 is dosed as needed, while Sermorelin is daily.
- 4PT-141 has high-quality evidence, while Sermorelin has moderate-quality evidence.
- 5They belong to different categories: PT-141 (Sexual Health) vs Sermorelin (Growth Hormone).
Which Is Better For...
PT-141
Those seeking an FDA-approved treatment with established safety data
Sermorelin
More budget-friendly option with lower monthly costs
PT-141
More convenient dosing schedule (as needed)
PT-141
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| PT-141 | $800 - $1,200/mo | FDA Approved | Cosette Pharmaceuticals (Covis Pharma) |
| Sermorelin | $150 - $350/mo | Withdrawn (off-label use continues) | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
PT-141 works via Melanocortin receptor agonist that activates central nervous system pathways involved in sexual. Sermorelin works via Bioidentical analog of growth hormone releasing hormone (GHRH) that stimulates natural GH. They differ in FDA approval status, efficacy data, and cost.
PT-141 typically costs $800 - $1,200/mo, while Sermorelin costs $150 - $350/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
PT-141 is FDA-approved. Sermorelin is not FDA-approved (Withdrawn (off-label use continues)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of PT-141 include Nausea, Flushing, Injection site reactions. Common side effects of Sermorelin include Injection site reactions, Flushing, Headache. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
PT-141 (Bremelanotide) is an FDA-approved peptide medication marketed as Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors like Viagra, PT-14...
View Full PT-141 GuideSermorelin is a bioidentical synthetic version of growth hormone releasing hormone (GHRH) consisting of the first 29 amino acids of the full 44-amino acid GHRH molecule. It was previously FDA-approved...
View Full Sermorelin GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between PT-141 and Sermorelin should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.